COMPREHENSIVE CANCER PROFILING THE POWER OF CLARITY Epic Sciences’ Comprehensive Cancer Profiling provides greater clarity, more efficiently. Using a single blood draw, this multi-technology approach leverages our proven and proprietary CTC capabilities, along with ctDNA and immune-cell analysis, enabling significant insights for both clinicians and drug development professionals focused on prostate and breast cancer. BIOPHARMA SOLUTIONS EPIC STORY VIDEO

THE CELL HOLDS THE ANSWERS,

AND OUR TESTS UNLOCK THOSE ANSWERS TO EXTEND LIVES.

TECHNOLOGY Epic Sciences' groundbreaking, unbiased approach using Comprehensive Cancer Profiling liquid biopsy platform, sees those rare cells that others miss. By peering more deeply into the single cell, we can perceive both genotype and phenotypes together, and delivering tests that are personalized, predictive and proven. We give cancer patients and their physicians the clear, accurate insights they need to choose the best course of therapy. LEARN MORE

AR-V7 TEST

The AR-V7 test is the first and only CTC-based liquid-biopsy test that is Medicare reimbursed and clinically-validated for men with metastatic castration-resistant prostate cancer (mCRPC). Requiring only a simple, non-invasive blood draw, this groundbreaking test empowers patients, with their doctors, the confidence to choose the most effective precision therapies.

LEARN MORE

BIOPHARMA SOLUTIONS

For pharmaceutical and clinical investigation partners, our program delivers a bias-free approach for cancer research, to develop clinical solutions that enhance drug development and provide valuable insights into the dynamics of cancer growth and evolution.

0
CANCER TYPES
0
ACADEMIC PARTNERS
0
PHARMACEUTICAL PARTNERS
>
0
PUBLICATIONS
>
0
CLINICAL TRIALS
>
0
SINGLE CTC GENOMES SEQUENCED
>
0
PATIENT SAMPLES CONTRACTED
VIEW OUR SOLUTIONS

WHAT SOURCES ARE SAYING

READ THE ARTICLES

Latest Tweets

WATCH EPIC SCIENCES VIRTUAL LAB TOUR

 EPIC SCIENCES IS CREATING A BREAKTHROUGH NEW CATEGORY OF CANCER DIAGNOSTICS. In a blood sample of a patient with metastatic cancer there are roughly 50 million cells and only about 5 are cancer cells with the potential to form tumors elsewhere in the body. Other diagnostics can’t see them, but we can. READ OUR
PUBLICATIONS